Biomedical Engineering Reference
In-Depth Information
Gilbert J, Henske P, Singh A (2003), Rebuilding Big Pharma's business model. In: In vivo: the
business and medicine report, 21(10),
www.elsevierbi.com
Gonzalez J, Sismeiro C, Dutta S, Stern P (2008) Can branded drugs benefi t from generic entry?
The role of detailing and price in switching to non-bioequivalent molecules. Int J Res Market
25:247-260
Grabowski H, Vernon J (1992) Brand loyalty, entry, and price competition in pharmaceuticals after
the 1984 Drug Act. J Law Econ 35(2):331-350
Grabowski H, Vernon J, DiMasi J (2002) Returns on research and development for 1990s new drug
introductions. Pharmacoeconomics 20(3):11-29
Grewal R, Chakravarty A, Ding M, Liechty J (2008) Counting chickens before the eggs hatch:
associating new product development portfolios with shareholder expectations in the pharma-
ceutical sector. Int J Res Market 25:261-272
Griliches Z, Cockburn I (1994) Generics and new goods in pharmaceutical price indexes. Am Econ
Rev 84(5):1213-1232
Hagedoorn J (1993) Understanding the rationale of strategic technology partnering: interorganiza-
tional modes of cooperation and sectoral differences. Strat Manag J 14:371-385
Hahn M, Park S, Krishnamurthi L, Zoltners AA (1994) Analysis of new product diffusion using a
four-segment trial-repeat model. Market Sci 13(3):224-247
Henderson R, Cockburn I (1994) Measuring competence? Exploring fi rm effects in pharmaceuti-
cal research. Strat Manag J 15:63-84
Henderson R, Cockburn I (1996) Scale, scope and spillovers: the determinants of research produc-
tivity in drug discovery. Rand J Econ 27(1):32-59
Higgins MJ, Rodriguez D (2006) The outsourcing of R&D through acquisitions in the pharmaceu-
tical industry. J Financ Econ 80:351-383
Hoang H, Rothaermel FT (2005) The effect of general and partner-specifi c alliance experience on
joint R&D project performance. Acad Manag J 48(2):332-345
Hollis A (2002) The importance of being fi rst: evidence from Canadian generic pharmaceuticals.
Health Econ 11:723-734
Hollis A (2003) The anti-competitive effects of brand-controlled “Pseudo-generics in the Canadian
pharmaceutical market”. Can Public Pol 29(1):21-32
Hollis A (2004) Me-too drugs: is there a problem? Mimeo, Department of Economics, University
of Calgary, Calgary
Hudson J (2000) Generic take-up in the pharmaceutical market following patent expiry: a multi-
country study. Int Rev Law Econ 20:205-221
Kanavos P, Costa-Font J, Seeley E (2008) Competition in off-patent drug markets: issues, regula-
tion and evidence. Econ Policy 23:499-544
Khulji SE, Mroczkowski T, Bernstein B (2006) From invention to innovation: toward developing
an integrated innovation model for biotech fi rms. J Prod Innov Manag 23:528-540
Lane PJ, Lubatkin M (1998) Relative absorptive capacity and interorganizational learning. Strat
Manag J 19:461-477
Lee J (2003) Innovation and strategic divergence: an empirical study of the U.S. pharmaceutical
industry from 1920 to 1960. Manag Sci 49(2):143-159
Magazzini L, Pammolli F, Riccaboni M (2004) Dynamic competition in pharmaceuticals. Eur J
Health Econ 5:175-182
Morton FMS (1999) Entry decisions in the generic pharmaceutical industry. Rand J Econ
30(3):421-440
Morton FMS (2000) Barriers to entry, brand advertising, and generic entry in the US pharmaceuti-
cal industry. Int J Ind Organ 18:1085-1104
Nerkar A, Roberts PW (2004) Technological and product-market experience and the success of
new product introductions in the pharmaceutical industry. Strat Manag J 25:779-799
PhRMA (2011) Pharmaceutical Industry Profi le 2011. PhRMA, Washington, DC
Powell WW, Koput KW, Smith-Doerr L (1996) Interorganizational collaboration and the locus of
innovation: networks of learning in biotechnology. Adm Sci Q 41(1):116-145
Search WWH ::
Custom Search